NCT06031909

Brief Summary

The goal of this study is to investigate the influence of frailty on clinical and stroke characteristics, treatment and outcomes in patients with acute stroke. The main questions it aims to answer are:

  1. 1.How prevalent is frailty in patients with stroke?
  2. 2.Which impairments (e.g. undernutrion, impaired mobility, laboratory markers) contribute to frailty?
  3. 3.Is the outcome of frail patients worse than those without?
  4. 4.Are in-hospital complications more frequent in frail patients than those without?

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Aug 2023

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2023

Completed
29 days until next milestone

First Submitted

Initial submission to the registry

August 30, 2023

Completed
12 days until next milestone

First Posted

Study publicly available on registry

September 11, 2023

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 31, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 31, 2024

Completed
Last Updated

September 11, 2023

Status Verified

September 1, 2023

Enrollment Period

1.3 years

First QC Date

August 30, 2023

Last Update Submit

September 7, 2023

Conditions

Keywords

frailtyoutcomeelderly

Outcome Measures

Primary Outcomes (2)

  • Prevalence of frailty in stroke patients

    Percentage of patients with frailty treated for stroke compared to all patients admitted for stroke

    30 days

  • Rate of good functional outcome

    Percentage of patients achieving a score of 0 to 2 on the modified Rankin scale (higher values indicating worse outcome, ranging from 0, no deficit, to 6, death) at 12 months follow-up

    12 months

Secondary Outcomes (6)

  • Patient reported outcome measures (PROM)

    12 months

  • Functional impairment in activities of daily living

    12 months

  • Mortality rate

    From date of admission until death or last follow-up, whichever comes first, assessed up to 12 months.

  • Cognitive outcome

    12 months

  • Rate of rehospitalization

    12 months

  • +1 more secondary outcomes

Study Arms (1)

Stroke patients

Stroke patients admitted to the certified stroke-unit of the Department of Neurology, University Hospital Giessen, Germany.

Diagnostic Test: Multimodal frailty assessment

Interventions

Different domains are assessed during hospital stay, these include: * Clinical scores: Clinical Frailty scale (CFS), Groningen Frailty index (GFI) * Brain frailty: assessing white matter hyperintensieties, atrophy and lacunar strokes in initial brain imaging * Laboratory values: laboratory Frailty index (FI-Lab), inflammatory markers * Nutrition: Controlling nutritional status score (CONUT-score), body mass index, dysphagia assessment (FOIS) * Mobility/strengths: de Morton Mobility Index (DEMMI), grip strenghts of non-paralytic arm via dynamometer, muscle mass estimated by sonographic measurement of the biceps brachii muscle and the rectus femoris muscle.

Stroke patients

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All patients admitted with the diagnosis of acute stroke treated at the certified stroke-unit will be included. All patients who consent for participation are further eligible for the outcome assessment.

You may qualify if:

  • treated at the certified stroke-unit of the Dpt. of Neurology, University Hospital Giessen
  • diagnosis of ischemic (including transient ischemic attack) or hemorrhagic stroke

You may not qualify if:

  • withdrawal of care within 24 hours after admission

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Neurology, University Hospital Giessen

Giessen, Hesse, 35392, Germany

RECRUITING

Related Publications (3)

  • Giede-Jeppe A, Bobinger T, Gerner ST, Sembill JA, Sprugel MI, Beuscher VD, Lucking H, Hoelter P, Kuramatsu JB, Huttner HB. Neutrophil-to-Lymphocyte Ratio Is an Independent Predictor for In-Hospital Mortality in Spontaneous Intracerebral Hemorrhage. Cerebrovasc Dis. 2017;44(1-2):26-34. doi: 10.1159/000468996. Epub 2017 Apr 19.

    PMID: 28419988BACKGROUND
  • Giede-Jeppe A, Reichl J, Sprugel MI, Lucking H, Hoelter P, Eyupoglu IY, Kuramatsu JB, Huttner HB, Gerner ST. Neutrophil-to-lymphocyte ratio as an independent predictor for unfavorable functional outcome in aneurysmal subarachnoid hemorrhage. J Neurosurg. 2019 Feb 1;132(2):400-407. doi: 10.3171/2018.9.JNS181975. Print 2020 Feb 1.

    PMID: 30717052BACKGROUND
  • Gerner ST, Reichl J, Custal C, Brandner S, Eyupoglu IY, Lucking H, Holter P, Kallmunzer B, Huttner HB. Long-Term Complications and Influence on Outcome in Patients Surviving Spontaneous Subarachnoid Hemorrhage. Cerebrovasc Dis. 2020;49(3):307-315. doi: 10.1159/000508577. Epub 2020 Jul 3.

    PMID: 32623428BACKGROUND

Related Links

MeSH Terms

Conditions

StrokeFrailty

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Stefan Gerner, MD

    Department of Neurology, University Hospital Giessen/Germany

    PRINCIPAL INVESTIGATOR
  • Thorsten Doeppner, MD

    Department of Neurology, University Hospital Giessen/Germany

    STUDY CHAIR
  • Hagen Huttner, MD, PhD

    Department of Neurology, University Hospital Giessen/Germany

    STUDY CHAIR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
12 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator, Associate professor

Study Record Dates

First Submitted

August 30, 2023

First Posted

September 11, 2023

Study Start

August 1, 2023

Primary Completion

October 31, 2024

Study Completion

October 31, 2024

Last Updated

September 11, 2023

Record last verified: 2023-09

Locations